Spyre Therapeutics Inc (SYRE)

01:51 AM

Best data tools to analyze Spyre Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com

01:51 AM

12:58 PM

What sentiment indicators say about Spyre Therapeutics Inc. stock2025 Performance Recap & Entry Point Strategy Guides - newser.com

12:58 PM

Oct 11, 2025

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat

Oct 11, 2025

Oct 10, 2025

Why Spyre Therapeutics Inc. stock is a value investor pickWeekly Profit Report & AI Powered Market Trend Analysis - newser.com

Oct 10, 2025

Oct 09, 2025

Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com

Oct 09, 2025

Oct 09, 2025

How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com

Oct 09, 2025

Oct 09, 2025

Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com

Oct 09, 2025

Oct 09, 2025

Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com

Oct 09, 2025

Oct 09, 2025

Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat

Oct 09, 2025

Oct 08, 2025

Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat

Oct 08, 2025

Oct 06, 2025

Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat

Oct 06, 2025

Oct 06, 2025

Published on: 2025-10-06 01:19:10 - newser.com

Oct 06, 2025

Oct 05, 2025

Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus

Oct 05, 2025

Oct 05, 2025

Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative

Oct 05, 2025

Oct 05, 2025

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times

Oct 05, 2025

Oct 05, 2025

6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan

Oct 05, 2025

Oct 05, 2025

Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com

Oct 05, 2025

Oct 05, 2025

Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com

Oct 05, 2025

Oct 05, 2025

Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com

Oct 05, 2025

Oct 05, 2025

Is Spyre Therapeutics Inc. (3920) stock inflation resilientMarket Risk Analysis & AI Driven Price Predictions - newser.com

Oct 05, 2025

Oct 03, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times

Oct 03, 2025

Oct 03, 2025

42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees - Stock Titan

Oct 03, 2025

Oct 03, 2025

What Fibonacci levels say about Spyre Therapeutics Inc. reboundJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com

Oct 03, 2025

Oct 03, 2025

Will Spyre Therapeutics Inc. stock pay special dividends2025 Macro Impact & Real-Time Volume Analysis - newser.com

Oct 03, 2025

Oct 03, 2025

What candlestick patterns are forming on Spyre Therapeutics Inc.Trend Reversal & Weekly High Conviction Ideas - newser.com

Oct 03, 2025

Oct 03, 2025

Why millennials buy Spyre Therapeutics Inc. (3920) stockTrade Risk Report & Smart Swing Trading Techniques - newser.com

Oct 03, 2025

Oct 03, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $54.29 Average PT from Brokerages - Defense World

Oct 03, 2025

Oct 02, 2025

What analysts say about Spyre Therapeutics Inc 3920 stockStock Watchlist Updates & Low Risk Capital Growth - earlytimes.in

Oct 02, 2025

Oct 01, 2025

What technical charts say about Spyre Therapeutics Inc. stockJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com

Oct 01, 2025

Sep 30, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Sep 30, 2025

Sep 30, 2025

Published on: 2025-09-29 23:52:21 - newser.com

Sep 30, 2025

Sep 30, 2025

Published on: 2025-09-29 23:49:14 - newser.com

Sep 30, 2025

Sep 29, 2025

Published on: 2025-09-29 13:35:29 - newser.com

Sep 29, 2025